Search

Savara Inc

Closed

SectorHealthcare

4.74

Overview

Share price change

24h

Current

Min

4.61

Max

4.8100000000000005

Key metrics

By Trading Economics

Income

-2.9M

-40M

EPS

-0.16

Employees

70

EBITDA

-2.9M

-40M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+137.1% upside

Dividends

By Acuity

Next Earnings

10 lis 2026

Market Stats

By TradingEconomics

Market Cap

-182M

992M

Previous open

4.74

Previous close

4.74

Savara Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

14 paź 2026, 19:36 UTC

Savara Inc shares fell modestly on Wednesday, retracing from an early peak and remaining under pressure below their 20-day moving average.

13 paź 2026, 20:13 UTC

Savara Inc shares advanced in after-market trading, continuing their upward trend since Tuesday's close, though still below the 20-day moving average.

12 paź 2026, 19:36 UTC

Social Media

Savara Inc shares are declining, having pulled back from an earlier high in pre-market hours, and are currently below their 20-day moving average.

9 paź 2026, 19:55 UTC

Social Media

JPMorgan sets a price target of $12 for Savara Inc, noting catalysts including anticipated UK approval in Q4 and a MAA in Q1 for molgramostim.

8 paź 2026, 23:25 UTC

Savara Inc shares advanced during after-market hours on Thursday, settling at a solid gain.

7 paź 2026, 20:01 UTC

News
Social Media

Savara Inc shares are trading sharply higher as JP Morgan initiated coverage with an Overweight rating and a $12 price target ahead of its PDUFA date.

6 paź 2026, 20:00 UTC

Savara Inc shares fell, breaking a trend of higher daily closes, indicating a shift in momentum following Monday's close.

2 paź 2026, 20:01 UTC

Savara Inc shares fell sharply, experiencing significant volatility and trading below their 20-day moving average amid high market volume.

1 paź 2026, 19:46 UTC

Social Media

Savara Inc shares are trading lower as heightened short interest and increased volume coincide with the approach of its PDUFA date for molgramostim.

30 wrz 2026, 21:03 UTC

Social Media

Savara Inc shares are trading higher in after-market hours amid speculation of a short squeeze ahead of its PDUFA date for molgramostim, with a market cap of $1 billion.

28 wrz 2026, 20:02 UTC

Social Media

Savara Inc is trading higher amid notable social media activity and unusual options bets, with a PDUFA date set for November 22.

25 wrz 2026, 20:07 UTC

Savara Inc shares fell sharply, continuing the downward trend with a cumulative return in negative territory and remaining below its 20-day moving average.

24 wrz 2026, 19:46 UTC

Savara Inc is trading higher, having previously peaked before a slight retracement, though it remains below its 20-day moving average.

23 wrz 2026, 22:01 UTC

Savara Inc gained in after-market trading following a brief decline earlier in the session, though it remains below its 20-day moving average.

22 wrz 2026, 20:05 UTC

Savara Inc's stock is declining sharply, moving from an initial gain to a notable drop, trading below its 20-day moving average.

21 wrz 2026, 20:12 UTC

Savara Inc is advancing in after-market trading, positioned above its 20-day moving average and near the upper end of its one-month range.

18 wrz 2026, 23:11 UTC

Savara Inc is trading modestly higher in after-market hours, reflecting the broader market's upward movement, with notable gains since Friday's close.

17 wrz 2026, 23:11 UTC

Savara Inc is seeing a modest upward move in after-market trading, currently near the upper end of its one-month range.

16 wrz 2026, 20:10 UTC

Savara Inc shares fell sharply today, continuing a decline since Tuesday and trading significantly below its 20-day moving average.

15 wrz 2026, 20:07 UTC

Savara Inc shares are lower, impacted by a sharp decline in the NY Empire State Manufacturing Index and rising oil prices amid broader market weakness.

11 wrz 2026, 20:08 UTC

Savara Inc. shares are trading lower today, continuing a decline since Thursday's close amid a broader market downturn.

10 wrz 2026, 20:03 UTC

Savara Inc. shares are lower today, reflecting broader market conditions amid the European Central Bank's recent interest rate hike and inflation projections.

4 wrz 2026, 19:26 UTC

Savara Inc shares are higher today, trading within a narrow range. The stock is currently near the lower end of its one-month range.

3 wrz 2026, 20:02 UTC

Savara Inc shares are lower during Thursday's session, retracing from an earlier peak amid rising jobless claims that may affect Federal Reserve policy.

2 wrz 2026, 20:08 UTC

Savara Inc. shares are higher today, driven by a significant upward trend in the Biotechnology sub-sector. No specific company news was identified.

1 wrz 2026, 19:36 UTC

Savara Inc. shares are lower today, continuing a decline since Monday. The stock remains below its 20-day moving average amid rising inflation concerns.

31 sie 2026, 22:01 UTC

Savara Inc. shares rose in after-market trading, advancing since Monday's close, despite earlier pulling back from a session high. No specific news was identified.

28 sie 2026, 21:02 UTC

In after-market trading, Savara Inc. has increased following a flat start, indicating upward momentum despite remaining below its 20-day moving average.

27 sie 2026, 23:56 UTC

Savara Inc shares are higher in after-market trading, despite no specific news. Broader market sentiment remains mixed amid ongoing inflation concerns and upcoming Fed guidance.

25 sie 2026, 19:16 UTC

Event

Savara Inc announced presentations at the ERS Congress, yet shares are trading lower today, reflecting a slight decline since Monday's close.

Peer Comparison

Price change

Savara Inc Forecast

Price Target

By TipRanks

137.1% upside

12 Months Forecast

Average 11.333 USD  137.1%

High 16 USD

Low 9 USD

Based on 6 Wall Street analysts offering 12 month price targets forSavara Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

6 ratings

6

Buy

0

Hold

0

Sell

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Savara Inc

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. is headquartered in Langhorne, Pennsylvania.
help-icon Live chat